Brief: Nektar Announces Clinical Trial Agreement To Evaluate Rezpegaldesleukin
24/02/2025 13:23
Feb 24 (Reuters) - Nektar Therapeutics NKTR.O :
* NEKTAR ANNOUNCES CLINICAL TRIAL AGREEMENT TO EVALUATE
REZPEGALDESLEUKIN IN PATIENTS WITH NEW ONSET TYPE 1 DIABETES
MELLITUS
Source text: ID:nPn3w8KGKa
Further company coverage: NKTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says